Search

Arcus Biosciences Inc

Открыт

СекторЗдравоохранение

22.48 -7.22

Обзор

Изменение цены акций

24 ч

Текущая

Мин.

23.25

Макс.

24.56

Ключевые показатели

By Trading Economics

Доход

37M

-91M

Продажи

24M

41M

Прибыль на акцию

-0.72

Рентабельность продаж

-221.951

Сотрудники

601

EBITDA

38M

-85M

Рекомендации

By TipRanks

Рекомендации

Покупка

Прогноз на 12 месяцев

+58.59% upside

Дивиденды

By Acuity

Следующий отчет о доходах

26 окт. 2026 г.

Рыночная статистика

By TradingEconomics

Рыночная капитализация

-362M

3.1B

Предыдущая цена открытия

29.7

Предыдущая цена закрытия

22.48

Arcus Biosciences Inc График

Прошлые результаты не являются надежным индикатором будущих результатов.

Связанные новости

8 окт. 2026 г., 20:07 UTC

Arcus Biosciences Inc shares are declining, closing significantly lower since Wednesday and near the bottom of their one-month range after an earlier session pullback.

7 окт. 2026 г., 19:46 UTC

Arcus Biosciences Inc shares are higher, having gained ground but remain below their 20-day moving average and near the lower end of their one-month range.

6 окт. 2026 г., 20:30 UTC

Arcus Biosciences Inc's shares declined in after-market trading, currently at their lowest point of the day and well below the 20-day moving average.

5 окт. 2026 г., 20:06 UTC

News

Arcus Biosciences Inc is advancing, supported by broader market movements, and has gained since Friday's close, despite earlier pulling back from a session high.

2 окт. 2026 г., 20:02 UTC

Arcus Biosciences Inc shares fell sharply, reversing earlier gains, and remain below their 20-day moving average amid ongoing weakness.

1 окт. 2026 г., 20:08 UTC

Correlated Moves

Nektar Therapeutics' disappointing Phase 2b study results contributed to a broader downturn in biotechnology, with the SPDR S&P Biotech ETF also lower.

30 сент. 2026 г., 20:07 UTC

News

Arcus Biosciences Inc shares are advancing modestly as Wedbush reiterates its Outperform rating and maintains a $43 price target.

29 сент. 2026 г., 20:07 UTC

Arcus Biosciences Inc is advancing, reflecting a notable increase since Monday's close, although it remains below its 20-day moving average.

28 сент. 2026 г., 19:15 UTC

Arcus Biosciences Inc is advancing, having reached a notable peak today, despite trading below its 20-day moving average and three prior sessions closing lower.

25 сент. 2026 г., 23:50 UTC

Arcus Biosciences Inc is trading lower in after-hours, reaching its lowest point of the day and remaining well below its 20-day moving average.

24 сент. 2026 г., 20:01 UTC

Arcus Biosciences Inc shares fell sharply, continuing a downward trend from Wednesday's close and trading well below its 20-day moving average.

23 сент. 2026 г., 20:07 UTC

Correlated Moves

Arcus Biosciences Inc shares fell amid a broader market downturn and rising U.S. Treasury yields, despite earlier reaching a session high.

22 сент. 2026 г., 20:06 UTC

Arcus Biosciences Inc is advancing amid a strong biotechnology sector, gaining ground since Monday's close but remains below its 20-day moving average.

21 сент. 2026 г., 19:16 UTC

Arcus Biosciences Inc is trading higher since Friday's close, despite being below its 20-day moving average and near the lower end of its one-month range.

18 сент. 2026 г., 20:13 UTC

Arcus Biosciences Inc is advancing in after-market trading following Friday's close, despite being positioned below its 20-day moving average.

17 сент. 2026 г., 19:36 UTC

Correlated Moves

Arcus Biosciences is advancing, building on prior momentum, amid a broader biotech sector uptick driven by positive Phase 3 results from Moderna's cancer vaccine trial.

16 сент. 2026 г., 23:06 UTC

Arcus Biosciences Inc is trading slightly higher in after-market hours, recovering from an earlier dip but remains below its 20-day moving average.

15 сент. 2026 г., 19:36 UTC

Correlated Moves

RCUS lower today, tracking declines in SPDR S&P Biotech ETF.

14 сент. 2026 г., 20:21 UTC

Arcus Biosciences Inc shares are lower in after-market hours, marking seven consecutive sessions of declines. No specific news was identified for the price movement.

11 сент. 2026 г., 21:21 UTC

Arcus Biosciences Inc shares are lower in after-market trading, continuing a recent trend. No specific company news was identified to explain the decline.

10 сент. 2026 г., 20:01 UTC

Arcus Biosciences Inc shares are sharply lower today, breaking a recent trend of higher closes. Unusually high trading volume may be influencing the decline.

9 сент. 2026 г., 20:07 UTC

News

Shares of Arcus Biosciences are lower today, despite anticipation of a significant data update in October following a recent presentation at Citigroup's summit.

8 сент. 2026 г., 20:07 UTC

Arcus Biosciences Inc shares are lower today, continuing a decline since Friday's close. The stock is trading near the lower end of its one-month range.

2 сент. 2026 г., 20:08 UTC

Correlated Moves

Arcus Biosciences Inc. shares are higher today, supported by gains in the biotechnology sector and trends in related ETFs. The stock has stabilized after fluctuations.

28 авг. 2026 г., 20:02 UTC

Arcus Biosciences shares are lower today, breaking a trend of higher closes. Rising U.S. Treasury yields may be impacting investor sentiment in biotechnology.

26 авг. 2026 г., 20:08 UTC

Arcus Biosciences Inc shares are lower during Wednesday's session amid mixed market performance and inflation data, with no specific company news identified for the decline.

20 авг. 2026 г., 19:36 UTC

Correlated Moves

Arcus Biosciences shares are lower, reflecting a broader decline in the biotechnology sector amid first-quarter results indicating a notable drop in price.

19 авг. 2026 г., 19:46 UTC

Correlated Moves

Arcus Biosciences Inc is trading higher, supported by a positive trend in the biotechnology sector. The stock remains above its 20-day moving average.

18 авг. 2026 г., 20:06 UTC

Arcus Biosciences Inc. shares are trading roughly flat amid no specific news. The stock remains above its 20-day moving average.

17 авг. 2026 г., 19:16 UTC

News

Arcus Biosciences Inc is rising as biotechnology sector momentum continues. The company reported second-quarter revenue of $41 million and a net loss of $91 million.

Сравнение c конкурентами

Изменение цены

Arcus Biosciences Inc Прогноз

Целевая цена

By TipRanks

58.59% рост

Прогноз на 12 месяцев

Средняя 38.6 USD  58.59%

Максимум 47 USD

Минимум 23 USD

Основано на мнении 11 аналитиков Wall Street, спрогнозировавших целевые цены для Arcus Biosciences Inc на следующие 12 месяцев – Данные за последние 3 месяца.

Консенсус по рейтингу

By TipRanks

Покупка

11 ratings

8

Покупка

3

Удержание

0

Продажа

Финансовые показатели

Расходы на продажи и администрирование

Операционные расходы

Прибыль до уплаты налогов

Продажи

Себестоимость реализации

Валовая прибыль от продаж

Процентные расходы по долгу

EBITDA

Операционная прибыль

$

О компании Arcus Biosciences Inc

Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's pipeline products include Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial; and AB308, an investigational anti-TIGIT monoclonal antibody, which is in Phase 1b clinical trial to study people with advanced solid and hematologic malignancies. It also develops Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in Phase 2 clinical trial; Quemliclustat, a small-molecule CD73 inhibitor, which is Phase 1b and Phase 2 clinical trial; Zimberelimab, an anti-PD-1 antibody, which is in Phase 2 clinical trial for metastatic cell lung cancer and monotherapy; and AB521, an oral and small-molecule inhibitor of HIF-2a, which is in Phase 1 clinical trial for the treatment of Von Hippel-Lindau disease. In addition, the company's preclinical pipeline products include AB598, a CD39 antibody; and AB801, a small molecule Axl inhibitor. It has a clinical collaboration with AstraZeneca to evaluate domvanalimab in combination with durvalumab in a registrational phase 3 clinical trial in patients with unresectable Stage 3 NSCLC; and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is headquartered in Hayward, California.
help-icon Live chat